Symbiosis Pharmaceutical Services, a global contract manufacturing organisation (CMO), has achieved a major milestone with the successful completion of its 1,000th sterile drug product batch.

Founded in 2011, the company has evolved from a Scottish startup into a globally recognised manufacturer of sterile injectable drug products. Over the last 14 years, Symbiosis has supported both clinical development and commercial supply across a diverse portfolio of therapeutic areas, including monoclonal antibodies (mAbs), antibody-drug conjugates (ADCs), viral vectors, small molecules, and advanced therapy medicinal products (ATMPs).

A significant highlight in its journey was its contribution to the development of the Oxford University/AstraZeneca COVID-19 vaccine, where the company produced nearly one million doses at its Stirling facility to support clinical trials and regulatory approvals in the UK.

“Reaching our 1,000th batch is a proud moment for everyone at Symbiosis,” said Colin MacKay, CEO of Symbiosis. “As global demand for sterile drug products rises, it reflects our commitment to manufacturing excellence and our shared purpose of helping deliver life-saving medicines to patients faster.”